Sort
10,766 grants matching “checkpoint inhibitor”
Exploring the Function of MHC-II/Lag3 Axis in Brain Metastasis to Develop Novel Therapeutic Strategies
$526,134Dihua Yu · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Exploring the Function of MHC-II/Lag3 Axis in Brain Metastasis to Develop Novel Therapeutic Strategies
$526,134Dihua Yu · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma
$526,128Abraham Ari Hakimi · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
Cyclin C-CDK8/19 kinases in development and in cancer
$525,969Piotr Sicinski · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Cyclin C-CDK8/19 kinases in development and in cancer
$525,969Piotr Sicinski · Dana-Farber Cancer Inst · R01 · FY2022 · CA
Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer
$525,898Jin Xie · University Of Georgia · R01 · FY2023 · CA
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma
$525,822J. Silvio Gutkind · University Of California, San Diego · R01 · FY2023 · CA
Analysis of the Functional Roles of a Novel G-alpha Nucleotide Cycle
$525,658John H Kehrl · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Modulation of the tumor microenvironment with probiotic therapies
$525,502Tal Danino · Columbia Univ New York Morningside · R01 · FY2024 · CA
Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment
$525,061Jianjun Gao · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
In vivo imaging of mitochondria structure and function in therapy resistant lung tumors
$524,804David B Shackelford · University Of California Los Angeles · R01 · FY2023 · CA
Dual-specificity phosphatase action in muscle disease
$524,744Anton M Bennett · Yale University · R01 · FY2022 · AR
Targeting HER2-low breast cancer with 17p loss
$524,740Xiongbin Lu · Indiana University Indianapolis · R01 · FY2023 · CA
Targeting HER2-low breast cancer with 17p loss
$524,740Xiongbin Lu · Indiana University Indianapolis · R01 · FY2022 · CA
Novel roles of PCSK9 in regulating the tumor immune microenvironment during radiotherapy
$524,375Yunyan Jennifer Jennifer Zhang · Duke University · R01 · FY2023 · CA
Precision targeting of T cell cytotoxicity with PET
$524,205Michael John Evans · University Of California, San Francisco · R01 · FY2021 · CA
Role of meningeal lymphatic vasculature in neuroimmune communication development
$524,089Jean-Leon Thomas · Yale University · R01 · FY2023 · NS
UCSF Project 1
$524,054Trever G Bivona · University Of California, San Francisco · U54 · FY2021 · CA
Plasmonic nanoparticle-mediated immunotherapy to treat metastatic cancer
$524,053Tuan Vo-Dinh · Duke University · R01 · FY2021 · EB
Targeting the cGAS/STING Pathway to Overcome Resistance to Immune Checkpoint Inhibitors in PTEN-deficient Prostate Cancer
$523,982Akash Patnaik · University Of Chicago · R01 · FY2023 · CA
Caspases in Inflammatory Cell Death Networks
$523,976Guy S Salvesen · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2020 · GM
Caspases in Inflammatory Cell Death Networks
$523,976Guy S Salvesen · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2019 · GM
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
$523,841Diane M Simeone · University Of California, San Diego · R01 · FY2024 · CA
Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC
$523,830Ralf Kittler · Ut Southwestern Medical Center · R01 · FY2024 · CA
Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy
$523,816Manish Bais · Boston University Medical Campus · R01 · FY2024 · DE